News
Six leaders working on LGBTQ+ inclusion in biopharma
4+ hour, 36+ min ago (55+ words) Endpoints News Six lead'ers work'ing on LGBTQ+ in'clu'sion in bio'phar'ma It's been a tough 18 months for the LGBTQ+ com'mu'ni'ty. The Amer'i'can Civ'il Lib'er'ties Union tracked 530 an'ti-LGBTQ bills across dozens " Think we're worth reading - tell Google. Confirm Endpoints as a trusted…...
Gan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma data
3+ hour, 13+ min ago (120+ words) Endpoints News We value your privacy We use third-party cookies that help us analyze how you use this website and store your preferences. However, you can opt out of these cookies by checking "Do Not Sell or Store My Personal…...
German biotech nets $50 M to advance two depression drugs, including Spravato challenger
12+ hour, 36+ min ago (67+ words) Endpoints News Ger'man biotech nets $50 M to ad'vance two de'pres'sion drugs, in'clud'ing Spra'va'to chal'lenger HM'NC Brain Health has se'cured $50 mil'lion in a Se'ries B fundraise de'signed to sup'port two psy'chi'a'try pro'grams in'to mid-stage stud'ies. The fam'i'ly-owned Ger'man drug'mak'er " Think we're…...
FDA approves Merck's Welireg-Keytruda combo as adjuvant treatment for kidney cancer
2+ day, 21+ hour ago (62+ words) Endpoints News FDA ap'proves Mer'ck''s Welireg-Keytru'da com'bo as ad'ju'vant treat'ment for kid'ney can'cer Mer'ck's Welireg and Keytru'da com'bi'na'tion won ap'proval as an ad'ju'vant treat'ment for kid'ney can'cer pa'tients af'ter surgery to re'move all or " Think we're worth reading - tell…...
Amgen and the FDA want two different outcomes for Tavneos. What will patients do?
3+ day, 39+ min ago (69+ words) Endpoints News Am'gen and the FDA want two dif'fer'ent out'comes for Tavneos. What will pa'tients do? Am'gen has asked the FDA to re'view ev'i'dence that its drug Tavneos (ava'co'pan), which treats a rare form of vas'culi'tis, is worth keep'ing on…...
Eli Lilly invests in startup Abridge for clinical trial recruitment
3+ day, 57+ min ago (60+ words) Endpoints News Eli Lil'ly in'vests in start'up Abridge for clin'i'cal tri'al re'cruit'ment Eli Lil'ly has in'vest'ed in Abridge as the health tech start'up ex'pands in'to clin'i'cal tri'al re'cruit'ment and broad'ens its reach in'to the life sci'ences. Think we're worth reading…...
Enliven prices $400 M offering; Jazz drug Zepzelca fails confirmatory study
3+ day, 3+ hour ago (45+ words) Endpoints News En'liv'en prices $400 M of'fer'ing; Jazz drug Zepzel'ca fails con'fir'ma'to'ry study Plus news about Cari'bou, Adi'al, and the Beneluxa Ini'tia'tive. Think we're worth reading - tell Google. Confirm Endpoints as a trusted biopharma news source...
Private jets, wildfire relief and $23, 000 internet: The 2025 oddities of biopharma executive pay
3+ day, 4+ hour ago (73+ words) Endpoints News Pri'vate jets, wild'fire re'lief and $23, 000 in'ter'net: The 2025 odd'i'ties of bio'phar'ma ex'ec'u'tive pay In comb'ing through thou'sands of C-suite pay pack'ages worth bil'lions of dol'lars, it's rare for a line item to stick out. Every once in a " Think…...
GSK took advantage of ASCO dip to get discount on Nuvalent
3+ day, 7+ hour ago (62+ words) Endpoints News GSK took ad'van'tage of AS'CO dip to get dis'count on Nu'va'lent GSK's $10. 6 bil'lion buy'out of Nu'va'lent, an'nounced Tues'day, was the largest in the com'pa'ny's his'to'ry. But did new CEO Luke Miels get " Think we're worth reading - tell Google....
Summit withdraws $500 M offering, citing 'market conditions"
4+ day, 1+ hour ago (56+ words) Summit withdraws $500 M offering, citing "market conditions" Endpoints News Sum'mit with'draws $500 M of'fer'ing, cit'ing 'mar'ket con'di'tion's' The cur'rent biotech en'vi'ron'ment can ap'par'ent'ly sup'port an in'dus'try-record IPO and si'mul'ta'ne'ous'ly ham'per ef'forts to raise half a bil'lion dol'lars. Sum'mit Ther'a'peu'tics ditched plans…...